Covid-19 roundup: Alexion's C5 inhibitor Ultomiris misses the PhIII bar; Lonza in waiting game to use ingredients in Moderna vaccine
C5 inhibition isn’t the answer to the search for treatments for severe Covid-19 after all.
Alexion is pausing enrollment to a Phase III study testing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
